U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
JERSEY, Channel Islands, Dec. 21, 2016 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chairman and Chief Executive Officer, Paul Cowan, will present at the 35th annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 10:00 a.m. Pacific Time at the Westin St. Francis on Union Square in San Francisco, CA.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Paul Cowan, Chairman & Chief Executive Officer — [email protected]; 215-497-7006
